COMMUNIQUÉS West-GlobeNewswire

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
13/10/2026
SYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced [...]
MBX Biosciences to Participate in Upcoming November Investor Conferences
13/10/2026
CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel [...]
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
13/10/2026
EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative [...]
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
13/10/2026
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis. ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic [...]
De l’océan au bien-être animal : Acadian lance la technologie d’alimentation optimisée Tasco®, conçue pour renforcer la résilience et la productivité
13/10/2026
DARTMOUTH, Nouvelle-Écosse, 13 oct. 2026 (GLOBE NEWSWIRE) -- Acadian Animal Wellness a annoncé aujourd’hui le lancement mondial de la technologie d’alimentation optimisée Tasco® destinée aux produits d’alimentation [...]
Rgenta Therapeutics Announces RGT-61159 Poster Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
13/10/2026
WOBURN, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for [...]
Envisagenics Awarded $2M+ NCI SBIR Grant to Expand AI-Driven RNA Splicing Analysis Capabilities Across Oncology Portfolio
13/10/2026
Funding will advance translational readiness across Envisagenics’ cancer-specific programs for internal development and strategic partnering NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Envisagenics, Inc. , an AI-driven [...]
TaiMed Biologics to Present Oral and Poster Presentations on TMB-365 and TMB-365/TMB-380 Combination Therapy at IDWeek 2026
13/10/2026
Company will present on a single-dose escalation study of TMB-365 and on resistance in the context of the long-acting TMB-365 and TMB-380 maintenance regimen in people living with HIV TAIPEI, Taiwan, Oct. 13, 2026 ( [...]
The Mindful CRNA Bootcamp Trains Nurses to Handle the Pressure of CRNA School
13/10/2026
Starting October 21, the live program helps nurses build the inner capacity that CRNA school demands. Founder Amanda Kay, MSN, CRNA, will close it with news about the platform's next chapter. CHICAGO, Oct. 13, 2026 ( [...]
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
13/10/2026
Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution 13. Oct 2026 / 08:15 CET/CEST, transmitted by [...]
Transactions in connection with share buy-back program
13/10/2026
Company announcement no. 39 - 26 13 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China
13/10/2026
BEIJING, Oct. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
Leo International Precision Health AG implements capital increase from company reserves
13/10/2026
Planegg / Martinsried, October 13, 2026 – Leo International Precision Health AG (“LIPH”, ticker symbol: LEOW), a holding company building a global integrated AI-driven healthcare ecosystem, is implementing the technical [...]
Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update
13/10/2026
Oslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its [...]
Teva to Host R&D Day on Wednesday, November 11 in New York City
12/10/2026
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s [...]

Pages